Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

Table 2 Parameters for final model (Model 2 [E ₅ ≠ E ₁₀ ]) with all covariates

Variable	Units	Mean value, θ ± SE	Intersubject variability, η ± SE
Placebo growth rate, r	10^-3 cm/day	46.0 ± 5.7	3.5 ± 2.1
Drug effect of 10 mg, E ₁₀	10^-3/day	3.9 ± 0.5	0.3 ± 0.2
Drug effect of 5 mg, E ₅	10^-3/day	2.3 ± 0.5	0.2 ± 0.2
Multiplicative effect of baseline SLD on placebo growth rate, θ1		0.4 ± 0.2	NA
Multiplicative effect of baseline SLD on drug effect, θ2		−0.7 ± 0.2	NA
Residual error, σ_ε	cm	1.1	NA

NA, not applicable; SE, standard error; SLD, sum of the longest tumor diameters.
Intersubject variability (η) denotes the standard deviation of the parameter distributions.

ISSN: 1471-2407